Noubar Afeyan - Apr 28, 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Director
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Stock symbol
MRNA
Transactions as of
Apr 28, 2022
Transactions value $
$0
Form type
4
Date filed
5/2/2022, 08:24 PM
Previous filing
Feb 14, 2022
Next filing
May 13, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $0 +703 +0.03% $0.00 2.24M Apr 28, 2022 Direct F1
holding MRNA Common Stock 3.92K Apr 28, 2022 By: Flagship Pioneering, Inc. F2
holding MRNA Common Stock 11.5M Apr 28, 2022 By: Flagship Venture Labs IV LLC F3
holding MRNA Common Stock 3.28M Apr 28, 2022 By: Flagship Ventures Fund IV, LP F4
holding MRNA Common Stock 2.84M Apr 28, 2022 By: Flagship Ventures Fund IV-Rx, LP F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Award $0 +5.42K $0.00 5.42K Apr 28, 2022 Common Stock 5.42K $142.52 Direct F6
transaction MRNA Restricted Stock Units Options Exercise $0 -703 -100% $0.00* 0 Apr 28, 2022 Common Stock 703 $0.00 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 Securities held by Flagship Pioneering, Inc. ("Flagship Pioneering"). Noubar B. Afeyan, Ph.D. is the CEO and a stockholder of Flagship Pioneering. Each of the reporting persons except for Flagship Pioneering disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F3 Shares held by Flagship VentureLabs IV LLC ("VentureLabs IV"). Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") is a member of VentureLabs IV and also serves as its manager. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole the manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F4 Shares held by Flagship Ventures Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F5 Shares held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F6 This option will become fully vested and exercisable on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.
F7 The shares subject to this restricted stock unit award vested in full on April 28, 2022.